---
layout: default
title: Palbociclib
parent: 僅模型預測 (L5)
nav_order: 591
evidence_level: L5
indication_count: 10
---

# Palbociclib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Palbociclib: From HR+/HER2− Breast Cancer to Acute Myeloid Leukemia (Leading Candidate Among 10 TxGNN Predictions)

## One-Sentence Summary

Palbociclib is a CDK4/6 inhibitor whose established use — per the collected literature in this evidence pack — is hormone receptor-positive (HR+), HER2-negative advanced breast cancer. TxGNN generated 10 candidate new indications, but the top-scored candidates (hyperthyroidism, rare congenital syndromes, thrombotic disease) have **zero supporting evidence or a contradicted mechanism**. The most clinically credible candidate is **Acute Myeloid Leukemia (AML)**, ranked 6th by score but supported by **5 clinical trials** including one completed Phase 1/2 study, giving it the pack's only L2 evidence level.

> ⚠️ Note on scope: the evidence pack's own formula points to `predicted_indications[0]` (hyperthyroidism, score 99.44%) as "the" predicted indication. That candidate's own rationale states *"no direct or indirect evidence; no known mechanistic link between CDK4/6 inhibition and thyroid hormone hypersecretion — a pure KG embedding artifact"* and is scored Hold/L5. Presenting it as the headline finding would be misleading, so this report leads with the best-evidenced candidate and provides the full ranking below for transparency.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | HR+/HER2− advanced/metastatic breast cancer (per collected literature; not present in structured `original_indications`) |
| Predicted New Indication | Acute Myeloid Leukemia (incl. MLL-rearranged AML) |
| TxGNN Prediction Score | 98.94% (rank 17,202 of all drug-disease pairs) |
| Evidence Level | L2 |
| Canada Market Status | Not Marketed (0 licenses on record — see caveat below) |
| Number of DINs | 0 |
| Recommended Decision | Proceed with Guardrails |

---

## Full Candidate Ranking (All 10 TxGNN Predictions)

| Rank | Disease | TxGNN Score | Evidence Level | Recommendation | Note |
|------|---------|-------------|-----------------|-----------------|------|
| 1 | Hyperthyroidism | 99.44% | L5 | Hold | No mechanistic link; pure embedding artifact |
| 2 | Rheumatoid arthritis | 99.36% | L4 | Research Question | 1 case report + 3 preclinical/cohort papers; plausible CDK6-synovial mechanism |
| 3 | Thrombotic disease | 99.32% | L5 | Hold | **Directionally reversed signal** — pharmacovigilance literature shows CDK4/6 inhibitors *increase* thromboembolism risk; not a treatment indication |
| 4 | Thyroid hormone resistance (THRB mutation) | 99.30% | L5 | Hold | No evidence; rare monogenic disease unrelated to CDK4/6 |
| 5 | Brachydactyly-syndactyly syndrome | 98.99% | L5 | Hold | No evidence; rare skeletal syndrome |
| **6** | **Myeloid leukemia (AML)** | **98.94%** | **L2** | **Proceed with Guardrails** | **5 trials, incl. 1 completed Phase 1/2 — strongest evidence in the set** |
| 7 | Multiple endocrine neoplasia | 98.86% | L5 | Hold | 26 trials retrieved are keyword mismatches ("endocrine therapy" in breast cancer vs. "endocrine neoplasia") |
| 8 | Colobomatous microphthalmia-rhizomelic dysplasia | 98.85% | L5 | Hold | No evidence; extremely rare congenital syndrome |
| 9 | Hyperthyroxinemia | 98.78% | L5 | Hold | No evidence |
| 10 | Prinzmetal angina | 98.75% | L5 | Hold | No evidence; no vascular smooth-muscle mechanism known |

This pattern — score clustering tightly between 98.7–99.4% with evidence quality varying from none to L2 — shows TxGNN's raw score is not a reliable proxy for repurposing plausibility here; literature/trial triangulation is what separates the one actionable candidate (AML) from the other nine.

---

## Why is This Prediction Reasonable?

Detailed structured mechanism-of-action data for palbociclib is not yet available in this evidence pack (flagged as data gap DG002, High severity, remediation pending a DrugBank API query). Based on the collected literature, however, palbociclib is consistently described as a CDK4/6 (cyclin-dependent kinase 4/6) inhibitor that blocks G1/S cell-cycle progression, and it is approved for HR+/HER2-negative metastatic breast cancer, typically combined with endocrine therapy.

Acute myeloid leukemia — particularly the MLL-rearranged subtype — is mechanistically a strong candidate for CDK4/6 blockade: this leukemia subtype has documented sensitivity to cell-cycle arrest at the G1/S checkpoint, which is why it has already attracted five independent clinical trials combining palbociclib with cytotoxic backbones (CPX-351, decitabine, sorafenib, dexamethasone). Because this represents an intra-oncology indication expansion (cancer → cancer) rather than a jump to an unrelated disease area, it carries the highest biological plausibility of the ten candidates.

By contrast, the top-ranked candidate by raw score, hyperthyroidism, and several other high-scoring candidates (thyroid hormone resistance, brachydactyly-syndactyly syndrome, hyperthyroxinemia, Prinzmetal angina) have no known mechanistic pathway connecting CDK4/6 inhibition to their pathophysiology, and no trials or literature were found on targeted searches (see query_log). The thrombotic disease candidate is a special case worth flagging separately: the literature retrieved actually documents palbociclib as *increasing* thromboembolic risk (FAERS disproportionality analyses, real-world cohorts), i.e., an adverse-event signal that TxGNN appears to have mis-scored as a therapeutic association.

---

## Clinical Trial Evidence (Myeloid Leukemia)

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT02310243](https://clinicaltrials.gov/study/NCT02310243) | Phase 1/2 | Unknown | 50 | Palbociclib in MLL-rearranged acute leukemias (AML/ALL), dose-finding based on prior solid-tumor experience; status unknown, results need follow-up |
| [NCT05627232](https://clinicaltrials.gov/study/NCT05627232) | Phase 1 | Recruiting | 24 | Palbociclib pre-treatment followed by CPX-351 for relapsed/refractory AML (Part 2 of a two-part study) |
| [NCT03844997](https://clinicaltrials.gov/study/NCT03844997) | Phase 1/2 | Completed | 35 | Palbociclib + CPX-351 in AML; evaluated safety/tolerability and overall response rate (CR/CRi) — the most mature dataset in this set |
| [NCT03878524](https://clinicaltrials.gov/study/NCT03878524) | Phase 1 | Terminated | 2 | SMMART PRIME basket trial with an AML arm; terminated with only 2 patients enrolled, low informational value |
| [NCT03132454](https://clinicaltrials.gov/study/NCT03132454) | Phase 1 | Active, not recruiting | 32 | Palbociclib alone and combined with sorafenib, decitabine, or dexamethasone in relapsed/refractory leukemia |

---

## Literature Evidence (Myeloid Leukemia)

Currently no related literature available.

---

## Canada Market Information

According to this evidence pack, Palbociclib has **no recorded market authorization** in Canada (market status: Not Marketed, 0 licenses, no DIN records). This appears inconsistent with palbociclib's well-established global regulatory status as an approved oncology drug and should be independently verified against the Health Canada Drug Product Database before this field is used in any decision — it may reflect a data collection gap in this pipeline rather than actual market absence.

---

## Cytotoxicity

Palbociclib is an antineoplastic agent (approved for breast cancer per collected literature; CDK4/6 kinase inhibitor mechanism), so this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (small-molecule CDK4/6 kinase inhibitor) |
| Myelosuppression Risk | High — literature in this pack explicitly lists "bone marrow suppression" among the class's common adverse events (PMID 37994878), consistent with palbociclib's well-documented neutropenia profile |
| Emetogenicity Classification | Not specified in this evidence pack — verify directly against the product label |
| Monitoring Items | CBC with differential (regular monitoring given myelosuppression risk); liver function |
| Handling Protection | Not specified in this evidence pack; follow standard institutional handling precautions for oral antineoplastic agents pending label confirmation |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Proceed with Guardrails** (for Acute Myeloid Leukemia only) — **Hold** on all other 9 candidates.

**Rationale:**
- AML is the only candidate with real trial density (5 studies, 1 completed Phase 1/2) and a coherent cell-cycle mechanism directly tied to a leukemia subtype (MLL-rearranged) known to be CDK4/6-dependent.
- The other 9 candidates either have no supporting evidence (L5) or, in the case of thrombotic disease, evidence pointing the opposite direction (a safety signal, not a therapeutic one) — none should be advanced.

**To proceed, the following is needed:**
- TFDA/Health Canada label warnings and contraindications (DG001, **Blocking** — currently prevents any S1 safety assessment)
- Structured mechanism-of-action record from DrugBank (DG002, High priority)
- Follow-up on NCT02310243's unresolved "Unknown" status and mature results from completed NCT03844997
- Verification of actual Canadian market/licensing status, given the apparent discrepancy noted above
- A myelosuppression monitoring plan appropriate to combination regimens (CPX-351, decitabine, sorafenib) before any guarded proceed decision is finalized
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

